Clinical Trial: Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TVAX-028 in the Treatment of Chronic Hepatitis B

U.S., June 30 -- ClinicalTrials.gov registry received information related to the study (NCT07673068) titled 'Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TVAX-028 in the Treatment of Chronic Hepatitis B' on May 28.

Brief Summary: This is a multicenter, open-label, non-randomized, Phase 1 clinical study with single-dose and multiple-dose dose-escalation cohorts. The study is designed to evaluate the safety, tolerability, and pharmacokinetic characteristics of TVAX-028 in patients with chronic hepatitis B virus infection

Study Start Date: May 31

Study Type: INTERVENTIONAL

Condition: HBV Infection

Intervention: DRUG: TVAX-028

TVAX-028 will be administered with adjuvant at low, medium, or high dose...